Clinical trials: Relapsed/ Refractory Multiple Myeloma
Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
Study of Pomalidomide, Cyclophosphamide, Dexamethasone in Relapsed/Refractory Multiple Myeloma
This study is being done to learn more about the drug, pomalidomide and to gather data on its safety and side effects when used in combination with commercially available cyclophosphamide and dexamethasone.
- Trial name
- NCT02176213
- Testing
- Pomalidomide, Cyclophosphamide, Dexamethasone
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Ajai Chari
Relapse/Refractory Multiple Myeloma
Clarithromycin,Lenalidomide and Dexamethasone for Relapsed/Refractory Myeloma
This phase II study investigating the efficacy and safety of a combination of biaxin,lenalidomide and dexamethasone in subjects with relapsed/refractory MM.
- Trial name
- NCT02986451
- Testing
- clarithromycin, Lenalidomide, Dexamethasone
- Where
- China
- Sponsor
- Sun Yat-sen University
Relapsed/Refractory Multiple Myeloma (MM)
Study of Naive HBI0101 CAR-T Therapy in Relapsed/Refractory Multiple Myeloma
A Phase 1a/1b Open-Label Study with Dose Escalation and Expansion Phases to Evaluate Safety and Preliminary Efficacy of Naïve HBI0101 CART Therapy for the Treatment of Relapsed/Refractory Multiple Myeloma.
- Trial name
- NCT07333430
- Testing
- Naive HBI0101 CAR-T
- Where
- Israel
- Volunteers
- 60 people
- Sponsor
- Hadassah Medical Organization
Relapsed/Refractory Multiple Myeloma
A Study Evaluating ABT-199 in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy
The primary objectives of this study are to assess the safety profile, characterize pharmacokinetics (PK) and determine the dosing schedule, maximum tolerated dose (MTD), and the recommended phase two dose (RPTD) of ABT-199 when…
- Trial name
- NCT01794507
- Testing
- ABT-199, bortezomib, dexamethasone
- Where
- 9 sites in United States, Australia and 1 more
- Volunteers
- 66 people
- Sponsor
- AbbVie
Multiple Myeloma, Non-Hodgkin's Lymphoma
Romidepsin in Combination With Lenalidomide in Adults With Relapsed or Refractory Lymphomas and Myeloma
The treatments used to treat lymphoma and multiple myeloma sometimes do not always work well or they may only work for a short period of time. This is why new treatments are being tested.
- Trial name
- NCT01755975
- Testing
- Romidepsin, Lenalidomide
- Where
- 7 sites in United States
- Volunteers
- 49 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Multiple Myeloma
Analysis of Effectiveness and Safety of Teclistamab in Relapsed and Refractory Multiple Myeloma Patients
200 adult patients with multiple myeloma receiving teclistamb will be included. Effectiveness, safety, and condition of use of teclistamab in early access program (post-MA) will be assessed.
- Trial name
- TEC-CARE (NCT06062537)
- Where
- 31 sites in France
- Volunteers
- 200 people
- Sponsor
- Intergroupe Francophone du Myelome
Multiple Myeloma and Plasma Cell Neoplasm
High-Dose Melphalan, Total-Body Irradiation, and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma in First Relapse
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00002630
- Testing
- filgrastim, cyclophosphamide, melphalan
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Mayo Clinic
Relapse/Refractory Multiple Myeloma
Safety, Activity and Cell Kinetics of CYAD-211 in Patients With Relapsed or Refractory Multiple Myeloma
The purpose of the IMMUNICY-1 study is to assess the safety, activity and cell kinetics of CYAD-211 in adults with relapsed or refractory multiple myeloma after a lymphodepletion regimen with fludarabine and/or cyclophosphamide
- Trial name
- IMMUNICY-1 (NCT04613557)
- Testing
- CYAD-211, Endoxan, Fludara
- Where
- 5 sites in United States, Belgium
- Volunteers
- 18 people
- Sponsor
- Celyad Oncology SA
Relapsed/Refractory Multiple Myeloma
Clinical Trial Using Humanized CART Directed Against BCMA (ARI0002h) in Patients With Relapsed/Refractory Multiple Myeloma to Proteasome Inhibitors, Immunomodulators and Anti-CD38 Antibody.
To assess the safety and efficacy of CARTBCMA ARI0002h in patients with relapsed/refractory multiple myeloma who have received treatment with proteasome inhibitor, immunomodulatory drug and anti-CD38 monoclonal antibody.
- Trial name
- NCT04309981
- Testing
- Adult differentiated autologous T-cells with anti-BCMA specificity
- Where
- 7 sites in Spain
- Volunteers
- 73 people
- Sponsor
- Sara V. Latorre
Multiple Myeloma
A Phase 1 Study of CNTO 328 (Siltuximab) in Relapsed or Refractory Multiple Myeloma
The purpose of this study is to assess the safety and the tolerability of siltuximab up to 11.0 mg/kg in combination with bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma.
- Trial name
- NCT01309412
- Testing
- Siltuximab
- Where
- 5 sites in Japan
- Volunteers
- 9 people
- Sponsor
- Janssen Pharmaceutical K.K.
Multiple Myeloma
Study of the Combination of Panobinostat & Carfilzomib in Patients With Relapsed &/or Refractory Multiple Myeloma
The purpose of this study is to find out what effects, good and/or bad, the combination of panobinostat and carfilzomib have on the patient's cancer.
- Trial name
- NCT01549431
- Testing
- Panobinostat, Carfilzomib, Dexamethasone
- Where
- 3 sites in United States
- Volunteers
- 32 people
- Sponsor
- Emory University
Multiple Myeloma and Plasma Cell Neoplasm
Bevacizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Trial name
- NCT00482495
- Testing
- bevacizumab, gene expression analysis, protein expression analysis
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Mayo Clinic
HLA-A*0201 Positive Cells Present, NY-ESO-1 Positive Tumor Cells Present
TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple Myeloma
This phase I trial studies the side effects of NY-ESO-1 TCR engineered peripheral blood mononuclear cells (PBMC) and peripheral blood stem cells (PBSC) after melphalan conditioning regimen in treating participants with multiple…
- Conditions
- HLA-A*0201 Positive Cells Present, NY-ESO-1 Positive Tumor Cells Present, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
- Trial name
- NYSCT MM (NCT03506802)
- Testing
- 18F-FHBG, Aldesleukin, Cellular Therapy
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Multiple Myeloma
Phase 1b Study of AEVI-007 in Subjects With Relapsed or Refractory Multiple Myeloma
This is a multicenter, open-label, dose-escalation Phase 1b study of AEVI-007 in subjects with relapsed or refractory Multiple Myeloma.
- Trial name
- NCT04671251
- Testing
- AEVI-007
- Where
- 7 sites in United States
- Volunteers
- 13 people
- Sponsor
- Avalo Therapeutics, Inc.
Multiple Myeloma
A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
This is a phase 1/2 multicenter, open-label, first-in-human study of IBI3003. It includes a phase 1 dose escalation and expansion section to identify maximum tolerated dose(MTD)/recommended Phase 2 Dose(RP2D) of IBI3003, plans to…
- Trial name
- NCT07336472
- Testing
- IBI3003
- Where
- 6 sites in United States
- Volunteers
- 360 people
- Sponsor
- Fortvita Biologics (USA)Inc.
Multiple Myeloma
Dose Escalation Study of JNJ-54767414 (Daratumumab) in Chinese Participants With Relapsed or Refractory Multiple Myeloma Who Failed at Least 2 Prior Lines of Systemic Therapy
The purpose of this study is to evaluate the tolerability, safety and the pharmacokinetic (PK) profile of daratumumab in Chinese participants with relapsed or refractory multiple myeloma (RRMM) who failed at least 2 prior lines…
- Trial name
- NCT02852837
- Testing
- Daratumumab
- Where
- 5 sites in China
- Volunteers
- 50 people
- Sponsor
- Janssen Research & Development, LLC
Relapsed or Refractory Multiple Myeloma
QUILT-3.005: A Study of N-803 in Patients With Relapsed or Refractory Multiple Myeloma
This is a Phase I/II, open-label, multi-center, competitive enrollment and dose escalation study of N-803 in patients with relapsed or refractory multiple myeloma.
- Trial name
- NCT02099539
- Testing
- N-803
- Where
- 4 sites in United States
- Volunteers
- 19 people
- Sponsor
- Altor BioScience
Leukemia, Lymphoma
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy
Ex vivo expanded human myeloid progenitor cells (hMPCs; CLT-008) have the potential to accelerate neutrophil recovery in patients receiving myeloablative conditioning as part of an umbilical cord blood transplant for hematologic…
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma, Plasma Cell Neoplasm
- Trial name
- NCT00891137
- Testing
- human myeloid progenitor cells
- Where
- 8 sites in United States
- Volunteers
- 30 people
- Sponsor
- Cellerant Therapeutics
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders
Studying Fentanyl in Patients With Cancer
RATIONALE: Studying blood samples from cancer patients undergoing pain treatment in the laboratory may help doctors learn more about how pain drugs work in the body.
- Conditions
- Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma
- Trial name
- NCT00899951
- Testing
- fentanyl citrate, pharmacological study
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Multiple Myeloma-Light Chain Only, Recurrent Plasma Cell Myeloma
Pomalidomide, Dexamethasone, and Filgrastim-sndz in Treating Patients With Relapsed or Refractory Multiple Myeloma
This phase I/II trial studies the side effects and the best dose of pomalidomide when given together with dexamethasone and filgrastim-sndz and to see how well they work in treating patients with multiple myeloma that has…
- Conditions
- Multiple Myeloma-Light Chain Only, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
- Trial name
- NCT01946152
- Testing
- Dexamethasone, Filgrastim-sndz, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- M.D. Anderson Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.